Company Description
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs.
The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics.
Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
| Country | United Kingdom |
| Founded | 2012 |
| IPO Date | Oct 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 483 |
| CEO | David Hallett |
Contact Details
Address: The SchrOedinger Building, Oxford Science Park Oxford, OX4 4GE United Kingdom | |
| Phone | 44 18 6581 8941 |
| Website | exscientia.ai |
Stock Details
| Ticker Symbol | EXAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| IPO Price | $22.00 |
| CIK Code | 0001865408 |
| CUSIP Number | 30223G102 |
| ISIN Number | US30223G1022 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Hallett Ph.D. | Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer and Executive Director |
| Ben R. Taylor | Chief Financial Officer, Chief Strategy Officer and Executive Director |
| Dr. John P. Overington Ph.D. | Chief Technology Officer |
| Sara Sherman | Vice President of Investor Relations |
| Dan Ireland | Executive Vice President of Legal and Company Secretary |
| Parker Moss | Executive Vice President of Corporate Development |
| Caroline Rowland | Chief People Officer |
| Richard Law | Chief Business Officer |
| Nikolaus Krall | Executive Vice President of Precision Medicine |
| Dr. Marie-Louise Helena Fjallskog M.D., Ph.D. | Interim Chief Medical Officer and Clinical Development Lead |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 25-NSE | Filing |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Nov 6, 2024 | 6-K | Report of foreign issuer |
| Oct 24, 2024 | 144 | Filing |
| Oct 10, 2024 | 6-K | Report of foreign issuer |